De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment

Overview

Journal Hemasphere

Publisher Wiley

Specialty Hematology

Date 2021 Nov 22

PMID 34805768

Authors

Despina Fotiou

Chrysanthi Skalioti

George Liapis

Smaragdi Marinaki

Efstathios Kastritis

Affiliations

Soon will be listed here.

References

Frerichs K, Bosman P, van Velzen J, Fraaij P, Koopmans M, Rimmelzwaan G . Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. Haematologica. 2019; 105(6):e302-e306. PMC: 7271608. DOI: 10.3324/haematol.2019.231860. View

Gertz M, Comenzo R, Falk R, Fermand J, Hazenberg B, Hawkins P . Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-28. DOI: 10.1002/ajh.20381. View

Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho A . A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124(15):2325-32. DOI: 10.1182/blood-2014-04-570010. View

Palladini G, Kastritis E, Maurer M, Zonder J, Minnema M, Wechalekar A . Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020; 136(1):71-80. PMC: 7332897. DOI: 10.1182/blood.2019004460. View

Doberer K, Klager J, Gualdoni G, Mayer K, Eskandary F, Farkash E . CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation. 2020; 105(2):451-457. DOI: 10.1097/TP.0000000000003247. View

Krejcik J, Casneuf T, Nijhof I, Verbist B, Bald J, Plesner T . Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016; 128(3):384-94. PMC: 4957162. DOI: 10.1182/blood-2015-12-687749. View

Le Q, Wood T, Alpers C . De novo AL amyloid in a renal allograft. Am J Nephrol. 1998; 18(1):67-70. DOI: 10.1159/000013308. View

Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M . Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2020; 28(1):3-11. DOI: 10.1080/13506129.2020.1798224. View

Kastritis E, Palladini G, Minnema M, Wechalekar A, Jaccard A, Lee H . Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021; 385(1):46-58. DOI: 10.1056/NEJMoa2028631. View

10.

Merlini G, Bellotti V . Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349(6):583-96. DOI: 10.1056/NEJMra023144. View

11.

Qian Q, Nasr S, Fidler M, Cornell L, Sethi S . De novo AL amyloidosis in the kidney allograft. Am J Transplant. 2011; 11(3):606-12. DOI: 10.1111/j.1600-6143.2010.03418.x. View

12.

Palladini G, Paiva B, Wechalekar A, Massa M, Milani P, Lasa M . Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer J. 2021; 11(2):34. PMC: 7887224. DOI: 10.1038/s41408-021-00428-0. View

13.

Dasari S, Theis J, Vrana J, Rech K, Dao L, Howard M . Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples. Mayo Clin Proc. 2020; 95(9):1852-1864. DOI: 10.1016/j.mayocp.2020.06.029. View

14.

Everly M, Everly J, Susskind B, Brailey P, Arend L, Alloway R . Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86(12):1754-61. DOI: 10.1097/TP.0b013e318190af83. View

15.

Kastritis E, Kostopoulos I, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M . Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018; 8(5):46. PMC: 5967299. DOI: 10.1038/s41408-018-0086-3. View